{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:36Z","timestamp":1791357456283,"version":"4.3.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/ajg.2015.106","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T08:07:03Z","timestamp":1430208423000},"page":"725-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain"],"prefix":"10.14309","volume":"110","author":[{"given":"Mazen M","family":"Jamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atoya B","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Peter","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"key":"R2-20-20210210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1090-3801(02)00143-X","article-title":"Recommendations for using opioids in chronic non-cancer pain.","volume":"7","author":"Kalso","year":"2003","journal-title":"Eur J Pain"},{"key":"R3-20-20210210","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1186\/ar1782","article-title":"Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids.","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R4-20-20210210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med"},{"key":"R5-20-20210210","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","article-title":"Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.","volume":"63","author":"Kurz","year":"2003","journal-title":"Drugs"},{"key":"R6-20-20210210","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/ACO.0b013e32834873e5","article-title":"Pharmacology of peripheral opioid receptors.","volume":"24","author":"Rachinger-Adam","year":"2011","journal-title":"Curr Opin Anaesthesiol"},{"key":"R7-20-20210210","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects.","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"R8-20-20210210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.mcg.0000225665.68920.df","article-title":"Lubiprostone: a chloride channel activator.","volume":"41","author":"Lacy","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R9-20-20210210","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10620-010-1515-8","article-title":"Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.","volume":"56","author":"Sun","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R12-20-20210210","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire.","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R13-20-20210210","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group.","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"R14-20-20210210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R15-20-20210210","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/biomet\/75.2.383","article-title":"A stagewise rejective multiple test procedure based on a modified Bonferroni test.","volume":"75","author":"Hommel","year":"1988","journal-title":"Biometrika"},{"key":"R16-20-20210210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and safety of lubiprostone in patients with chronic constipation.","volume":"55","author":"Barish","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R17-20-20210210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.","volume":"103","author":"Johanson","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R18-20-20210210","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14656566.2011.566559","article-title":"Lubiprostone for the treatment of opioid-induced bowel dysfunction.","volume":"12","author":"Wong","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R22-20-20210210","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study.","volume":"12","author":"Michna","year":"2011","journal-title":"J Pain"},{"key":"R23-20-20210210","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.2174\/138161212803582388","article-title":"Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal?","volume":"18","author":"Holzer","year":"2012","journal-title":"Curr Pharm Des"},{"key":"R24-20-20210210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6904-10-12","article-title":"Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderatesevere chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.","volume":"10","author":"Lowenstein","year":"2010","journal-title":"BMC Clin Pharmacol"},{"key":"R27-20-20210210","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","article-title":"Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.","volume":"55","author":"Sloots","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R28-20-20210210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12013-012-9406-6","article-title":"Methadone but not morphine inhibits lubiprostone-stimulated Cl(-) currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl(-) currents.","volume":"66","author":"Cuppoletti","year":"2013","journal-title":"Cell Biochem Biophys"},{"key":"R30-20-20210210","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s10620-011-1801-0","article-title":"Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.","volume":"56","author":"Lembo","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R31-20-20210210","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2036.2011.04983.x","article-title":"Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.","volume":"35","author":"Chey","year":"2012","journal-title":"Aliment Pharmacol Ther"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2015106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201505000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:09:51Z","timestamp":1786547391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201505000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2015.106","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}